Listen on the go
CORRECT!
Next question
touchCARDIO touchCARDIO
Atherosclerosis
Watch Time: 2 mins 32

Charalambos Antoniades, ESC 2021 – High-sensitivity C-reactive Protein, Perivascular Adipose Tissue and Atherosclerosis

Share this Video
Copy Link
Published Online: Sep 24th 2021

Prof. Charalambos Antoniades (Professor of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK) kindly shared his thoughts on the use of high-sensitivity C-reactive protein as a biomarker in clinical decision making, and the role of perivascular adipose tissue in the pathogenesis of atherosclerosis from the virtual ESC Congress 2021.

Questions

  1. What is the rationale for the use of high-sensitivity C-reactive protein (hsCRP) as a biomarker in clinical decision making and what are its limitations? (0.15)
  2. What have we learned about the role of perivascular adipose tissue in the pathogenesis of atherosclerosis? (1.08)

Speaker disclosures: Prof. Charalambos Antoniades is founder, shareholder and director of Caristo Diagtnostics. 

Support: Interview and filming supported by Touch Medical Media and conducted by Heather Hall.

Filmed during a remote video call with Prof. Charalambos Antoniades as a highlight of ESC 2021, August 2021.

Related Videos In Atherosclerosis
Atherosclerosis
Developed by Touch
Brian Bergmark, ACC 2022: TRANSLATE-TIMI 70: Effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol
Watch Time: 7 mins

The TRANSLATE-TIMI 70 trial looks at the effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol. touchCARDIO spoke with Dr Brian Bergmark (Brigham and Women’s Hospital, Boston, MA) about the use of vupanorsen and the safety and efficacy of the TRANSLATE-TIMI 7 trial. Questions: What is vupanorsen and what is […]

Atherosclerosis
Developed by Touch
Paul Ridker, ACC 2022: Secondary analysis of the CANTOS trial of the inflammatory hypothesis of atherothrombosis and chronic kidney disease
Watch Time: 6 mins

The CANTOS trial assessed the differential impact of residual inflammatory risk and residual cholesterol risk among atherosclerosis patients with and without chronic kidney disease. touchCARDIO spoke to Prof Paul Ridker (Harvard University, Boston, MA, USA) to discuss his presentation at the American College of Cardiology Annual Meeting 2022 entitled ‘Secondary Analysis of the CANTOS Trial: […]

Atherosclerosis
Charalambos Antoniades, ESC 2021 – The Fat Attenuation Index
Watch Time: 8 mins 45

Prof. Charalambos Antoniades (Professor of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK) kindly shared his thoughts on the fat attenuation index and its use in clinical decision making from the virtual ESC Congress 2021. Questions Can you tell us a little about the fat attenuation index (FAI) and how it can be […]

Trending In Atherosclerosis:

Brian Bergmark, ACC 2022: TRANSLATE-TIMI 70: Effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol
Atherosclerosis
    • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72